US Patent Issued to The Schepens Eye Research Institute on May 13 for "Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1)" (Massachusetts Inventors)

ALEXANDRIA, Va., June 12 -- United States Patent no. 12,295,985, issued on May 13, was assigned to The Schepens Eye Research Institute Inc. (Boston).

"Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1)" was invented by Dong Feng Chen (Newtonville, Mass.) and Chenying Guo (Malden, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is a method of promoting neuronal growth by administering IGFBPL-1, or an agent that increases or stabilizes IGFBPL-1 activity to a subject in need thereof, e.g., a subject in need of treating optic nerve degeneration."

The patent was filed on Dec. 2, 2022, under Application No. 18/073,9...